Oncology News

Certain women who had their ovaries removed during a hysterectomy for benign conditions faced higher risks for all-cause mortality, CVD and cancer, a recent study showed.

Black and Asian women with early-stage, hormone-receptor positive, HER2-negative, node-negative breast cancer appeared about twice as likely as their white counterparts to experience locoregional recurrence.

Cancers diagnosed during pregnancy or 1 year post-partum had greater overall 5-year mortality compared with those not diagnosed near pregnancy, but risks were not the same for all cancer sites, researchers reported in JAMA Oncology.

The Healio Editors compiled a list of recent news from the Society of Gynecologic Oncology Annual Meeting held from March 25-28, 2023.

Racial and ethnic subtype-specific differences in pathologic complete response rates after neoadjuvant chemotherapy for breast cancer may partially account for worse survival rates for Black women, according to study data.

A cloud-based chatbot considerably improved identification of high-risk pathogenic variants in cancer genes, according to study results.

A digital tool that tracks patient-reported symptoms helped identify post-discharge complications among women with gynecologic cancer who underwent debulking surgery, according to retrospective study results.

Niraparib did not significantly extend OS among women with recurrent ovarian cancer, according to long-term follow-up results of the ENGOT-OV16/NOVA trial presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Neoadjuvant therapy with olaparib showed feasibility for women with germline-mutant ovarian cancer, according to results of the NOW trial presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Compared with other people with breast cancer, those with a preexisting severe mental illness were less likely to receive appropriate treatment and more likely to experience delays in receiving treatment, findings in Psycho-Oncology showed.